Search
Now showing items 1-10 of 64
Inhibition of monoamine oxidase by phthalide analogues
(Elsevier, 2013)
Based on recent reports that the small molecules, isatin and phthalimide, are suitable scaffolds for the
design of high potency monoamine oxidase (MAO) inhibitors, the present study examines the MAO inhibitory
properties ...
The design and evaluation of an l-dopa-lazabemide prodrug for the treatment of Parkinson’s disease
(MDPI, 2017)
l-Dopa, the metabolic precursor of dopamine, is the treatment of choice for the symptomatic relief of the advanced stages of Parkinson’s disease. The oral bioavailability of l-dopa, however, is only about 10% to 30%, and ...
The monoamine oxidase inhibition properties of C6- and N1-substituted 3-methyl-3,4-dihydroquinazolin-2(1H)-one derivatives
(Springer, 2020)
Quinazolinone compounds are of interest in medicinal chemistry since they display a wide range of biological properties. In the present study, a series of C6- and N1-substituted 3-methyl-3,4-dihydroquinazolin-2(1H)-one ...
Exploring 4-substituted-2-thiazolylhydrazones from 2-, 3-, and 4-acetylpyridine as selective and reversible hMAO-B inhibitors
(Elsevier, 2013)
A series of 4-substituted-2-thiazolylhydrazone derivatives have been synthesized and tested in vitro for
their human monoamine oxidase (hMAO) A and B inhibitory activity. Our findings confirmed that the
substitution at ...
The interactions of caffeine with monoamine oxidase
(Elsevier, 2013)
Aims: Caffeine has been used as a scaffold for the design of inhibitors of monoamine oxidase (MAO) A and B.
Substitution at the C8 position with a variety of moieties yields structures with high MAO inhibition ...
Azure B and a synthetic structural analogue of methylene blue, ethylthioninium chloride, present with antidepressant-like properties
(Elsevier, 2014)
Aims: The phenothiazinium compound, methylene blue (MB), possesses diverse pharmacological actions and is
attracting attention for the treatment of bipolar disorder and Alzheimer's disease. MB acts on both monoamine
oxidase ...
The monoamine oxidase inhibition properties of selected structural analogues of methylene blue
(Elsevier, 2017)
The thionine dye, methylene blue (MB), is a potent inhibitor of monoamine oxidase (MAO) A, a property that may, at least in part, mediate its antidepressant effects in humans and animals. The central inhibition of MAO-A ...
Inhibition of monoamine oxidase by benzoxathiolone analogues
(Elsevier, 2016)
Inhibitors of the monoamine oxidase (MAO) enzymes are considered useful therapeutic agents, and are used in the clinic for the treatment of depressive illness and Parkinson’s disease. In addition, MAO inhibitors are also ...
Caffeine as a lead compound for the design of therapeutic agents for the treatment of Parkinson’s disease
(Bentham Science, 2015)
The current pharmacological therapies for the treatment of Parkinson’s disease are mostly inadequate and recent, improved therapeutic agents are required. Two important molecular targets for the design of anti-parkinsonian ...
Evaluation of natural and synthetic 1,4-naphthoquinones as inhibitors of monoamine oxidase
(Wiley, 2016)
Previous reports have documented that 1,4-naphtho-
quinones act as inhibitors of the monoamine oxidase
(MAO) enzymes. In particular, fractionation of the
extracts of cured tobacco leafs has led to the charac-
terization ...